What is the appropriate treatment for pink eye (conjunctivitis)?

Treatment of Pink Eye (Conjunctivitis)

For uncomplicated bacterial conjunctivitis in immunocompetent patients, prescribe a 5-7 day course of topical moxifloxacin 0.5% three times daily, which provides superior gram-positive coverage and achieves 81% complete resolution at 48 hours, though mild cases often resolve spontaneously without treatment. 1

Immediate Red Flags Requiring Same-Day Ophthalmology Referral

Before initiating any treatment, exclude these vision-threatening conditions:

• Visual loss or decreased vision – indicates possible keratitis, uveitis, or intraocular pathology 1, 2
• Moderate to severe pain (beyond mild irritation) – suggests keratitis, uveitis, or acute angle-closure glaucoma 1, 3
• Corneal involvement (opacity, infiltrate, ulcer on examination) – requires urgent specialist evaluation 1, 3
• Severe purulent discharge – raises concern for gonococcal infection, which can cause corneal perforation within 24 hours 1, 3
• History of herpes simplex virus eye disease – high risk of recurrence requiring specialist management 1, 2
• Immunocompromised state – increased risk of atypical or severe infections 1, 2
• Contact lens wear – higher risk of Pseudomonas keratitis requiring aggressive coverage 1
• Recent ocular surgery or trauma – associated with sight-threatening complications 3, 4

Determining the Etiology

Viral Conjunctivitis (Most Common Overall)

Clinical features:

• Watery discharge with follicular reaction on inferior tarsal conjunctiva 1, 3
• Preauricular lymphadenopathy (especially with adenovirus) 1, 3
• Often unilateral initially, becoming sequentially bilateral within days 3
• Concurrent upper respiratory infection common 1, 3
• Abrupt onset with chemosis and eyelid swelling 3

Treatment approach:

• Supportive care only – refrigerated preservative-free artificial tears four times daily and cold compresses 1
• Avoid topical antibiotics – they provide no benefit, cause unnecessary toxicity, and promote resistance 1, 5
• Topical antihistamines (e.g., olopatadine) may relieve itching and discomfort 1
• Patient education: Highly contagious for 10-14 days from symptom onset; strict handwashing with soap and water; avoid sharing towels/pillows; virus survives on surfaces up to 28 days 1, 3
• Self-limited, typically resolving within 5-14 days 1, 3

Special consideration for HSV conjunctivitis:

• Usually unilateral with vesicular rash or ulceration of eyelids 3
• Treat with topical ganciclovir 0.15% gel three to five times daily OR trifluridine 1% solution five to eight times daily PLUS oral antivirals (acyclovir, valacyclovir, or famciclovir) 1
• Never use topical corticosteroids in HSV without antiviral coverage – they potentiate viral replication and can cause corneal perforation 1

Bacterial Conjunctivitis (Second Most Common Infectious Cause)

Clinical features:

• Mucopurulent or purulent discharge with matted eyelids on waking 1, 5
• Papillary (not follicular) conjunctival reaction 3
• Lack of itching and no history of prior conjunctivitis favor bacterial etiology 5
• Can be unilateral or bilateral 3

Treatment algorithm:

1. Mild disease in immunocompetent adults:

   • Often self-limited – 64% resolve spontaneously by days 6-10 without treatment 1
   • Consider observation alone OR topical antibiotics to shorten duration and enable faster return to work/school 1, 5
   • Topical antibiotics provide earlier clinical remission (68.2% cure vs 55.5% with placebo by days 4-9) 1, 6

2. Moderate to severe disease:

   • First-line: Topical moxifloxacin 0.5% three times daily for 5-7 days 1
   • Alternative fluoroquinolones: Levofloxacin, gatifloxacin, ciprofloxacin, or besifloxacin 1
   • Non-fluoroquinolone alternatives: Gentamicin, tetracycline, or ofloxacin 0.3% four times daily if fluoroquinolones unavailable 1
   • No single antibiotic demonstrates superiority – choice based on convenience, cost, and local resistance patterns 1, 5

3. If no improvement after 48-72 hours:

   • Obtain conjunctival cultures and Gram stain 1
   • Consider MRSA (42% of staphylococcal isolates show fluoroquinolone resistance) – may require compounded topical vancomycin 1
   • Consider gonococcal or chlamydial infection requiring systemic therapy 1

Resistance considerations:

• Geographic resistance varies significantly – Pseudomonas resistance to moxifloxacin increased from 19% to 52% in some regions 1
• MRSA isolates generally resistant to fluoroquinolones but susceptible to vancomycin 1

Gonococcal Conjunctivitis (Vision-Threatening Emergency)

Clinical features:

• Marked eyelid edema, bulbar conjunctival injection, profuse purulent discharge 3
• Preauricular lymphadenopathy 3
• Can cause corneal perforation within 24 hours if untreated 1, 3

Treatment:

• Systemic therapy mandatory: Ceftriaxone 250 mg IM single dose PLUS azithromycin 1 g oral single dose 7, 1
• Add topical antibiotics and saline lavage for comfort 1
• Daily ophthalmology follow-up until complete resolution 1, 2
• Obtain conjunctival cultures and Gram stain before initiating treatment 7, 1
• Hospitalization may be necessary 2
• Treat sexual partners concurrently 1, 2

Chlamydial Conjunctivitis

Clinical features:

• Mucopurulent discharge, follicular reaction 3
• Often associated with genitourinary symptoms 3

Treatment:

• Systemic therapy required (topical alone insufficient): 7, 1
  • Azithromycin 1 g oral single dose OR
  • Doxycycline 100 mg oral twice daily for 7 days OR
  • Levofloxacin 500 mg oral once daily for 7 days
• Pregnant patients: Azithromycin 1 g oral single dose OR amoxicillin 500 mg oral three times daily for 7 days 7
• More than 50% of infants have concurrent infection at other sites (nasopharynx, lungs) – systemic coverage essential 1, 2
• Treat sexual partners and consider sexual abuse in children 7, 1
• Re-evaluate after treatment completion (19% failure rate) 1

Allergic Conjunctivitis

Clinical features:

• Itching is the hallmark symptom 1, 5
• Bilateral watery discharge 3
• May have concurrent allergic rhinitis or asthma 1, 3
• Absence of preauricular lymphadenopathy and matted eyelids 3

Treatment:

• First-line: Topical antihistamines with mast cell-stabilizing properties (olopatadine, ketotifen) 1, 2
• Adjunctive measures: Cold compresses, refrigerated preservative-free artificial tears, sunglasses as allergen barrier 1, 2
• Persistent symptoms: Add mast cell stabilizers 2
• Severe cases: Brief 1-2 week course of low side-effect profile topical corticosteroids (fluorometholone, rimexolone, or loteprednol) with IOP monitoring 1
• Avoid chronic use of topical vasoconstrictors – cause rebound vasodilation 1
• Oral antihistamines may worsen dry eye and exacerbate symptoms 1

Neonatal Conjunctivitis (Ophthalmia Neonatorum)

Requires immediate pediatric and ophthalmology consultation:

Gonococcal (onset 24-48 hours after birth):

• Marked eyelid edema, profuse purulent discharge 3
• Treatment: Ceftriaxone 25-50 mg/kg IV or IM single dose (max 250 mg) PLUS topical antibiotics and saline lavage 7, 3
• Admit for observation with daily ophthalmology follow-up 3
• Risk of corneal perforation within 24 hours without treatment 3

Chlamydial (onset 5-12 days after birth):

• Milder purulent discharge than gonococcal 3
• Treatment: Erythromycin base or ethylsuccinate 50 mg/kg/day oral divided into 4 doses for 14 days 7, 3
• 80% clinical cure rate; second 14-day course may be needed 3
• Screen for concurrent pneumonia (staccato cough, tachypnea) 3

Prophylaxis:

• Erythromycin 0.5% ophthalmic ointment in each eye single application at birth 7

Special Populations and Situations

Contact Lens Wearers:

• Always treat with topical antibiotics due to Pseudomonas risk 1, 8
• Reserve fluoroquinolones (ofloxacin, ciprofloxacin) for more aggressive coverage 1
• Discontinue lens wear until complete resolution 2
• Refer to ophthalmology to evaluate for corneal ulcers 8

Suspected MRSA:

• Consider in nursing home residents or community-acquired infections 1
• If unresponsive to fluoroquinolones within 48-72 hours, may require compounded topical vancomycin 1

Limited Antibiotic Access:

• Povidone-iodine 1.25% ophthalmic solution may be as effective as topical antibiotics 1, 2

When to Use Topical Corticosteroids (With Extreme Caution)

Indications (only with close ophthalmology supervision):

• Severe adenoviral conjunctivitis with marked chemosis, severe lid swelling, epithelial sloughing, or membranous conjunctivitis 1
• Corneal subepithelial infiltrates post-adenoviral infection (occurring ≥1 week after onset) causing blurring and photophobia 1

Monitoring requirements:

• Measure IOP periodically to detect steroid-induced glaucoma 1
• Perform pupillary dilation to evaluate for cataract 1
• Re-evaluate within 1 week for severe cases 1
• Taper slowly to minimum effective dose 1
• Avoid prolonged use (>2 weeks) without ophthalmology supervision 1

Absolute contraindications:

• Never use in HSV conjunctivitis without antiviral coverage – potentiates infection and can cause corneal perforation 1
• Avoid in suspected viral conjunctivitis unless HSV definitively excluded 1

Follow-Up Strategy

• Bacterial conjunctivitis: Return if no improvement in 3-4 days 1, 2
• Viral conjunctivitis: Return if symptoms persist beyond 2-3 weeks or worsen 3
• Gonococcal conjunctivitis: Daily visits until complete resolution 1
• Chlamydial conjunctivitis: Re-evaluate after treatment completion 1
• Patients on topical corticosteroids: Regular IOP measurement and slit-lamp examination 1, 3

Critical Pitfalls to Avoid

• Using topical antibiotics for viral conjunctivitis – no benefit, causes toxicity, promotes resistance 1, 5
• Using topical corticosteroids indiscriminately – prolongs adenoviral infections, worsens HSV infections, causes elevated IOP and cataracts 1, 2
• Missing gonococcal conjunctivitis – delayed referral leads to corneal perforation and vision loss 1
• Topical therapy alone for chlamydial/gonococcal conjunctivitis – systemic treatment mandatory 1, 2
• Failing to consider sexual abuse in children with gonococcal or chlamydial conjunctivitis 7, 1
• Prolonged trifluridine use (>2 weeks) – causes epithelial toxicity 1
• Inadequate patient education about contagiousness – facilitates community spread 1, 2